ANTCHAIN
23.6.2021 10:52:08 CEST | Business Wire | Press release
AntChain, Ant Group’s technology brand, today launched a developer community support program at its first developer conference. The program is designed to further foster trusted industry collaboration networks with blockchain, secure computing, IoT, and other innovative technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210623005429/en/
This new program will bring AntChain's technical know-how and industry experience to partners and developers across a variety of platforms. Among them, the AntChain open technology platform will serve to accelerate the development of blockchain applications as well as reduce costs, while the AntChain open business ecosystem will help connect partners and developers with complementary business opportunities and operational resources. A new talent certification system has also been put in place to support technical professionals’ career development through training and certification standards.
So far, the AntChain developer community has included over 330 institutional partners and nearly 10,000 developers, who together have created over 30 innovative industry applications, including an eSign electronic contracting service and a blockchain-powered rural property trading platform with NDSCSoft.
“With the further digitalization of our economy and society, we have seen trends shifting from the digitalization of single organizations to the digitalization of industry partnerships and collaborations,” said Geoff Jiang, President of Ant Group’s Intelligent Technology Business Group. “We are committed to working more closely with our partners and developers to explore new synergies, resolve pain points in industry collaborations, and uncover greater value for the global economy and our societies."
During the conference, developers from across various industries also shared their experience and best practices on integrating AntChain's technology into their day-to-day operations. “AntChain's technology can help strengthen the efficiency of multi-party collaborations, while enhancing trust in traditional rural property transactions, in turn acting as a frictionless and more efficient solution for customers in rural areas,” said Wang Liping, Deputy General Manager of NDSCSoft.
At today's conference, AntChain also announced the launch of a suite of new innovative technologies and products, including the Blockchain Transmission Network (BTN), a high-speed, long-distance blockchain communication technology, and the AntChain Module-as-a-Service (MaaS) integrated computing module for simplified blockchain deployment.
BTN improves the data throughput and stability of blockchains through high-speed communications technology. It can enhance the throughput of a blockchain network by 186%, reduce its bandwidth cost by 80%, and cut transmission latency by 40%.
AntChain MaaS lowers the technical and financial costs of deploying blockchain hardware, and ensures the security and immutability of data transmission with technologies including silicon root of trust, digital signature at source and end-to-cloud integration.
AntChain’s technologies and solutions have been deployed in more than 50 use cases typically involving multi-party collaborations, including supply chain finance, IT leasing, global shipping, cross-border remittance, and more. On June 10, AntChain also announced a five-year global partnership with UEFA to jointly explore how blockchain technology can be used to accelerate the digital transformation of the football industry.
About AntChain
AntChain is Ant Group’s technology brand. According to IPR Daily and patent database IncoPat, Ant Group held the highest number of published blockchain-related patent applications between 2017 and the six months ended June 30, 2020. Since the launch of Ant Group’s blockchain business in 2016, the company pioneered the use of AntChain in over 50 blockchain commercial applications and use cases, including supply chain finance, cross-border remittance, charitable donations, and product provenance.
The AntChain platform consists of three layers including the underlying Blockchain-as-a-Service open platform, the digitalization of assets, and the circulation of digitalized assets. By enabling businesses to digitalize their assets and transactions, AntChain establishes trust in multi-party collaborations. The AntChain platform generated over 100 million daily active items such as patents, vouchers, and warehouse receipts, for the twelve months ended June 30, 2020.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210623005429/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom